Combination Therapy for Overactive Bladder: Who Approves?

Affiliations

¹ Tufts University School of Medicine and the Division of Urology, St. Elizabeth Medical Center, Steward Health, Boston, Massachusetts, USA. Electronic address: staskin@att.net.

Editorial

David R Staskin. Eur Urol. 2018 Oct.

. 2018 Oct;74(4):510-511.

doi: 10.1016/j.eururo.2018.06.014. Epub 2018 Jun 20.

¹ Tufts University School of Medicine and the Division of Urology, St. Elizabeth Medical Center, Steward Health, Boston, Massachusetts, USA. Electronic address: staskin@att.net.

No abstract available

Comment on

Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER. Gratzke C, et al. Eur Urol. 2018 Oct;74(4):501-509. doi: 10.1016/j.eururo.2018.05.005. Epub 2018 Jun 1. Eur Urol. 2018. PMID: 29866467 Clinical Trial.